21+
Age Verification
You must be 21 years of age or older to enter this site.
By entering, you confirm you are 21 years of age or older.
You must be 21 years of age or older to enter this site.
By entering, you confirm you are 21 years of age or older.
GLP1-SE is an acylated GLP-1 analogue engineered for extended pharmacokinetic profiles in preclinical research. This 31-amino acid peptide features a C18 fatty diacid moiety that facilitates albumin binding, significantly extending its circulating half-life compared to native GLP-1 in laboratory models.
As a selective GLP-1 receptor agonist, semaglutide has been extensively characterized in peer-reviewed literature across multiple large-scale clinical studies. Its molecular architecture represents a refined approach to incretin-based receptor engagement, making it one of the most widely studied research peptides in the GLP-1 class.
AXOM GLP1-SE is manufactured under strict cGMP-equivalent protocols and verified to ≥99% purity via reverse-phase HPLC. Each lot is accompanied by a Certificate of Analysis documenting identity, purity, peptide content, and endotoxin levels. Available in 10mg and 20mg lyophilized formats.
Selective GLP-1 receptor engagement with high binding affinity — extensively characterized across multiple large-scale in-vivo research studies.
C18 fatty diacid conjugation enables prolonged albumin binding and extended receptor engagement in preclinical pharmacokinetic studies.
≥99% HPLC-verified purity with full COA documentation. Every lot independently tested by third-party analytical laboratories.
Landmark phase 3 study evaluating semaglutide's receptor activity profile in a large randomized, double-blind, placebo-controlled setting. Demonstrated robust and consistent GLP-1 receptor engagement with a once-weekly administration protocol over 68 weeks in 1,961 participants.
Phase 3 study extending the characterization of semaglutide's pharmacological profile in subjects with comorbid metabolic conditions. Confirmed the compound's dose-dependent activity across multiple metabolic biomarkers over a 68-week observation period.
Pivotal cardiovascular outcomes trial evaluating semaglutide's long-term pharmacological activity profile over a median 2.1-year observation period in 3,297 subjects. Provided foundational data on the compound's sustained receptor engagement and systemic activity characteristics.
| Product Name | GLP1-SE (Semaglutide) |
| Synonyms | Ozempic peptide (research reference) |
| CAS Number | 910463-68-2 |
| Molecular Formula | C187H291N45O59 |
| Molecular Weight | ~4,113.58 Da |
| Sequence Length | 31 amino acids |
| Receptor Targets | GLP-1 (selective agonist) |
| Modification | C18 fatty diacid at Lys-26 via linker (albumin-binding) |
| Purity | ≥99% (Reverse-Phase HPLC) |
| Form | Lyophilized white powder |
| Available Sizes | 10mg, 20mg |
| Solubility | Soluble in sterile water, bacteriostatic water |
| Endotoxin | <1 EU/μg (LAL method) |
| Certification | COA included with every order |
| Intended Use | For research and laboratory use only |
GLP1-SE is supplied as a lyophilized powder and should be reconstituted with sterile bacteriostatic water (BAC water) for research applications.
All orders ship within the continental United States via USPS or UPS. Peptides are shipped at ambient temperature — lyophilized peptides are stable during transit. Free shipping on orders over $250.
